Renalyte Medical

Company Overview

Snapshot

Founded in August 2021 by Yaniv Ben Haim, Nava Barit Ben David, and Ehud Jacobzon, Renalyte Medical operates with 1-10 employees. The company has secured two funding rounds and holds two US patents. In August 2025, Renalyte Medical received a grant from the Israel Innovation Authority.

Business overview

Renalyte Medical is developing a fully implantable Renal Assist Device (RAD) designed to provide continuous, 24/7 blood filtration as an alternative to traditional hemodialysis. The system utilizes a Safe-by-Design architecture with a venous-only approach to blood access, aiming to reduce surgical barriers and long-term clinical risks. This technology seeks to transform End-Stage Renal Disease (ESRD) care from intermittent, clinic-based treatment to a continuous, internal solution, aligning with value-based kidney care mandates. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In December 2025, Renalyte Medical was featured on Israel’s Economy Channel, where Danny Roup discussed the disruptive potential of their fully implantable, venous-only dialysis alternative. This media exposure highlights the market validation for an internal, continuous filtration system, signaling to investors the company's potential to significantly disrupt the traditional $10 billion dialysis market and address the need for more efficient kidney care solutions.

Company Intelligence Q&A

What is Renalyte Medical's core product?

Renalyte Medical is developing a fully implantable Renal Assist Device (RAD) designed to provide continuous, 24/7 blood filtration as an alternative to traditional hemodialysis.

When was Renalyte Medical founded and by whom?

Renalyte Medical was founded in August 2021 by Yaniv Ben Haim, Nava Barit Ben David, and Ehud Jacobzon.

Has Renalyte Medical received any grants?

Yes, in August 2025, Renalyte Medical secured a grant from the Israel Innovation Authority.

What is the strategic advantage of Renalyte Medical's technology?

The company's technology uses a venous-only approach to blood access, eliminating complications associated with arterial-venous pressure gradients, which lowers the surgical barrier for implantation and reduces long-term clinical risk.

What was a recent notable public mention for Renalyte Medical?

In December 2025, Renalyte Medical was featured on Israel’s Economy Channel, where the disruptive nature of its fully implantable renal assist solution was highlighted.